Surrey Heartlands

Joint Formulary & PAD

Idarucizumab - Anticoagulation reversal

You are here : Home > Formulary Search > Idarucizumab - Anticoagulation reversal

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
  • Intravenous injection (IV)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Idarucizumab
Indication :
Anticoagulation reversal
Group Name :
Keywords :
anticoagulant reversal, dabigatran antidote, dabigatran reversal
Brand Names Include :
Praxbind
Important Information :
Dabigatran anticoagulant reversal. RESTRICTED to Haematologists only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Idarucizumab is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Anticoagulation reversal.

Committee Recommendations (1)

04 Sep 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.